CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Other Financing Activities

Financing cash flows not reported separately.

CRISPR Therapeutics AGNASDAQ: CRSP

Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026

Other financing activities declines year over year

Q3 FY2026 other financing activities of $4.45M fell 76.1% year over year, ahead of the -85.3% change in trailing-twelve-month other financing activities.

Context

  • Other financing activities amounted to 0.0% of revenue in FY2025, down 89.4 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -76.1% holds above the trailing-twelve-month pace of -85.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.45M+497.0% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$3.33M-85.3% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.1%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 other financing activities of $3.33M is the 2nd largest of the 7 companies compared; the peer median is $667K.
  • Its year-over-year change of -85.3% is the 5th highest of 7, against a peer median of +9.7%.
  • Other financing activities amounts to 13.2% of revenue for CRSP, versus a peer median of 1.5%.
CRSP Competitors Peer median
Other Financing Activities for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$107.66M +412.7%—122.6%
CRSPCRISPR Therapeutics AGLTM Sep 2026$3.33M -85.3%—13.2%
EDITEditas Medicine, Inc.LTM Mar 2026$2.89M +200.7%—7.5%
BEAMBeam Therapeutics Inc.LTM Jun 2026$1.63M -140.9%—1.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$1.33M -80.6%+46.8%2.0%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$0 +100.0%-21.1%0.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding CRSP) $667K+9.7%+12.8%1.5%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
Deferred Income Tax00000
Stock-Based Compensation102.39M97.95M81.03M86.57M72.5M
Change in Working Capital26.86M19.85M(193.59M)156.27M71.88M
Accounts Receivables(161K)305K(200M)175M25M
Inventory(37.51M)0000
Accounts Payables37.51M5.16M(20.25M)044.89M
Other Working Capital27.02M14.38M26.66M(18.73M)1.99M
Other Non-Cash Items14.11M12.47M(14.05M)(38.62M)72.73M
Operating Cash Flow538.97M(495.74M)(260.38M)(142.77M)(345.01M)
Capital Expenditures(81.71M)(37.19M)(9.47M)(1.9M)(914K)
Acquisitions (Net)953.73M221.47M000
Purchases of Investments(1.51B)(1.42B)(1.07B)(1.49B)(1.01B)
Sales of Investments555.6M1.2B1.45B1.21B1.01B
Other Investing Activities(953.73M)(221.47M)(2.5M)0(34M)
Investing Cash Flow(1.04B)(258.66M)374.65M(280.48M)(31.81M)
Debt Repayment00000
Common Stock Issued213.27M970K62.66M300.7M426.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities37.68M37.62M031.29M0
Financing Cash Flow250.95M38.59M62.66M331.98M426.03M
Effect of Forex Changes(11K)(80K)656K(21K)95K
Net Change in Cash(245.52M)(715.88M)177.59M(91.29M)49.3M
Free Cash Flow457.27M(532.93M)(269.85M)(144.68M)(345.93M)

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.